The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM Podcast from The Journal of Nuclear Medicine.

Moderators: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany) and Heiko Schoder, MD, MBA (Memorial Sloan Kettering Cancer Center)

Panelist: Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center)

Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/